A B S T R A C T Cytidine deaminiase, an enzyme that catalyses the deamination of both cytidine and its nucleoside analogues including the antineoplastic agents cytosine arabinoside (ara-C) and 5-azacytidine (5-azaC), lhas been partially purified from normal and leukemic humiian granulocytes. The purification procedure included lheat precipitation at 700 C, ammoniunm sulfate precipitation, calcium phosphate gel ionl exchange, and Sephadex G-150 gel filtration. The enzymlle has mol xvt 51,000, isoelectric pH of 4.8, and maximlum activity over a broad pH range of 5-9.5. The enzyme is stabilized by the presence of the sulfhydryl reagent, dithiothreitol.
5-fluorocytidine and 5-bromo-2'-deoxycytidine also exhiibited substrate activity, with maximum velocities greater than that of the physiologic substrates cytidine anid deoxycytidine. No activity was observed witlh nucleotides or (leoxyniucleotides. The relative maximumlii velocity of the enzyme for cytidine and its nucleoside analogues remaiie(l constanit during purification, inidicating that a single enzynme was responsible for deaminiatioln of these substrates.
Tetrahydrouridine (THU) was founid to be a strong competitive inhibitor of partially purified deamiiinase with a KT of 5.4 X 10' M.
The biochemical properties of partially purified preparations of cytidine deaminase froimi normal anid leukemic cells were compared with respect to isoelectric pH, molecular weight, and substrate atn(d inllibitor kinetic parameters, andlno differences were observed. However, normal circulating granulocytes contained a significantly greater concenitr-ation of cytidiine deaminase (3.52±1.86 AL'ccived for pulblicatiotn 5 Septemiiber 1973 and in revised formii 5 Novemiber 1973. X 10'/nmg protein) than chronic myelocytic leukemia (CML) cells (1.40±0 .70 X 10' U/mg proteini) or acute myelocytic leukemia (AML) cells (0.19+0.17 X 103 U/ mg protein). To explain these differences in enzyme levels in leukemic versus normal cells, the changes in cytidine deaminase levels associated with maturation of nornmal granulocvtes were studied in niormal human bone marrow. Myeloid precursors obtained from bone marrow aspirates were separated into mature and immature fractions by Ficoll density centrifugation. Deaminase activity in lysates of mature granulocytes was 3.55-14.2 times greater than the activity found in the lysates of immature cells. Decreased enzyme activity was also found in immature myeloid cells from a patient with CML as compared to mature granulocytes from the same patient. These observations support the conclusion that the greater specific activity of cytidine deaminase in normal mature granulocytes as compared to leukemic cells is related to the process of granulocyte maturation ratlher than a specific enzymatic defect in leukemic cells.
INTRODUCTION
(ytosine arabinoside (ara-C)' and 5-azacytidine (5- azat('), both analogues of the naturally occurring nucleosi(le cytidine, have become important agents in the treatmlent of lhuman acute leukemia (1, 2) . These agents are converted to active triphosphate derivatives by kinases found in normal and tumor tissue (3, 4) and are subject to inactivation by the enzyme cytidine deaminase found in human liver, plasma, and( red blood cells, as well as various tumors (5) (6) (7) (8) .
'-lbbreviations uised in this paper: AML, acute myelocytic leukemia; ara-C, cytosine arabinoside; 5-azaC, 5-azacyti(linic; CML, clhronic miyelocytic leuikemia; dCMP, deoxycyti(iine monophosphate; DTT, (lithiothreitol; PBS, sodium chloride solution, 0.15 M, buffered with potassium phosphate, pH 7.4; THU, tetrahydrouridine.
In addition, Silber, Gabrio, and Huennekens (9, 10) have described cytidine deaminase activity in homogenates of normal and leukemic granulocytes. Interest in the granulocyte enzyme has been heightened by a recent report by Steuart and Burke, which suggested that the pretreatment level of cytidine deaminase in leukemic cells may determine the response of patients to ara-C (11). These workers have also described a progressive rise in deaminase levels in leukemic cells during treatment with ara-C, a finding that correlated with the development of clinical resistance to this agent.
Because of the importance of ara-C and 5-azaC in the treatment of acute myelocytic leukemia (AML) and the possible role of deaminase in the development of resistance to these agents, we have undertaken the purification and biochemical characterization of this enzyme from normal and leukemic human granulocytes. In addition, the changes in deaminase levels associated with granulocyte maturation were investigated in an effort to explain the higher levels of enzyme activity observed in normal granulocytes as opposed to leukemic cells.
METHODS
Enzyme isolation from granulocytes. Approximately 2 X 10'°granulocytes were obtained from normal human volunteers and from patients with chronic myelocytic leukemia (CML) and acute myelocytic leukemia (AML) by leukapheresis with a "Leukapak" unit containing a nylon fiber filter (Fenwal, Morton Grove, Ill.) as previously described (12) . Granulocytes were released from the filter at the conclusion of the run by washing with a solution of plasma anticoagulated with acid citrate dextrose. The recovered cells included greater than 99% granulocytes as determined from Wright stain smears.
Leukemic granulocytes were also obtained from the peripheral blood of patients with AML or CML either before treatment or during periods of marked leukocytosis while receiving hydroxyurea or busulfan therapy. No patient had received ara-C or 5-azaC at any time before this study. All leukemic patients had more than 20,000 leukocytes/mm' of peripheral blood, and 67-98% of these In the second assay procedure, ammonia production was measured by a coupled enzymiie reaction with glutamic acid dehydrogeniase as previously described (8, 14) . This assay was used for determining reaction velocities of other substrates as compared to cytidline, and in the determination of Michaelis constanits for 5-azaC and the halogenated substrates, 5-fluorocytidine (Hoffman-La Roche, Inc., Nutley, N. J.), 5-bromo-2'-deoxycytidine and 5-iodo-2'-deoxycytidine (both from Schwarz-Mannl Div., Becton, Dickinson & Co., Orangeburg, N. Y.).
Enzymze units. 1 U of enzyme activity was defined as the hydrolysis of 1 nmole of substrate per hour at 37'C.
Enzyme purification. The crude leukocyte extract was immersed in a 70'C water bath for 6 mIi with constant agitation, and denatured protein was removed by centrifugation at 5,000g for 15 min. The suipernlate of approximately 10 ml was diluted to 20 ml with 0.1 M Tris-Cl, pH 7.5, containing 5 X 10-3 M dithiothreitol (DTT). Ammonium sulfate, 36.1 g/100 ml, was adlded wvith stirring to bring the solution to 60% satuiration, and the precipitate, coIntaining the cytidine deaniinase activity, was collected by centrifugation at 27,000g for 20 miii. The precipitate was resuspended in 2 ml of 0.01 M Tris-Cl buffer, pH 7.0, with 2.5 x 10-3 M DTT, anid (lialyzed against 500 vol of this buffer for 18 h. 250 mgn of aged calcium phosplhate gel (Sigma Chemical Co., St. Louis, Mo.) was added to the enzyme solution and the supernate discarded after centrifugation at 5,000g for 10 miii. The enzyme was then eluted by resuspending the gel in 2 ml of 0.05 M phospliate buffer, pH 7.0, with 2.5 X 10-3 M DTT; the calcium phosphate gel was removed by ceiitrifugation and discarded. The supernate was subjected to a second ammonium sulfate precipitation at 60% saturation and the precipitate dissolved in 0. 10 U of enzyme activity in the crude extract. The mean specific activity of deaminase in granulocytes from 10 normal volunteers was 3.52±1.86 X 10' U/mg protein (Table I ) with a somewhat higher mean value for women than for men (4.54 vs. 2.84 X 10' U/mg protein). In contrast, the mean enzyme level in granulocytes from 10 patients with CML was 1.40±0.70 X 10' U/mg protein, and the mean for eight patients with AML was 0.19+0.17 x 103 U/mg protein. No significant difference between enzyme levels in men and women was seen in the leukemic patients. The differences in deaminase activity between normal granulocytes and CML cells, between normal granulocytes and AML cells, and between CML and ANIL cells were significant at the P < 0.005 level.
Enzyme purification. A summary of typical purification of the enzyme from normal granulocytes is presented in Table II . The peak fractions from Sephadex G-150 gel filtration had a specific activity of greater than 2.5 X 106 U/mg protein, representing 700-fold purification, with a recovery of 18% of original activity in these fractions. The limited amount of protein present in peak fractions (Amso = 0.02 or less) prevented further definition of enzyme purity by disk electrophoresis. The purification of the deaminase from CML and AML cells is also depicted in Table II . The behavior of these enzymes during purification closely resembles that of the deaminase from normal granulocytes. The small quantity of enzyme found in AMIL cells prevented purification beyond the calcium phosphate step.
Substrate specificity. As shown in Table III , cytidine deaminase from normal granulocytes showed a broad specificity for cytidine derivatives, including cytidine, deoxycytidine, the pharmacologic agents ara-C and 5-azaC, and the 5-halogenated analogs. Among the naturally occurring nucleosides, the partially purified deaminase had greatest affinity for cytidine (Michaelis constant 1.1 X 10' M); the Michaelis constants for ara-C and 5azaC were 8. 
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cytidine, while no activity was detected for the free base, cytosine, or the nucleotides CMP, dCTP, and CTP. The relative rate of deamination of deoxycvtidine, ara-C, 5-azaC, and the halogenated derivatives as compared to cytidine did not change during purification (Table IV) suggesting that a single enzyme was responsible for the deamination of these compounds. Deamination of dCAIP was detected when this substrate was incubated with the crude extract; however, this activity was eliminated by heating to 70°C during purification of cytidine deaminase; in addition dCMP did not competitively inhibit the deamination of cytidine, a further indication that these two substances were not substrates for the same enzyme.
Other enzyme properties. The enzyme from normal and leukemic cells was stable as a crude extract for several months at 4°C without loss of activitv. However, more highly purified fractions rapidly lost activity unless protected by a sulfhydryl reagent such as dithiothreitol. Peak fractions obtained from the final purification steps were stable for only 2-3 days at 4°C or -90°C despite the inclusion of DTT. No dialyzable cofactors appear to be present, as judged by the enzymes stability during an 18-h dialysis before the calcium phosphate step. A mlolecular weight of 51,000 was indicated for the enzyme from normal granulocytes and CML cells by gel filtration on Sephadex G-200. The enzyme displaye(d a broad range of maximum activity between pH 5 and pH 9.5 (Fig. 1) . The isoelectric point of both normal and CML enzyme was 4.8 as determined by isoelectric focusing in a pH gradient of 4-6 (Fig. 2) . In the peak fractions obtained by isoelectric focusing, enzyme specific activity was increased only four-fold over starting activity. This considerable loss of enzyme activity with little change in purity prevented the use of this procedure in the enzyme purification scheme.
Inhibition of cytidine dearninase by THU. THU. a known inhibitor of human liver cytidine deaminase (22) , strongly inhibited the partially purified deaminase from normal granulocytes; the Ki's for THU determined with cytidine ( Fig. 3) and deoxycytidine as substrates were 5.4 X 10" M and 5.5 X 10-8 M, respectively. The inhibition appeared to be competitive in that the Vnma with cytidine as substrate was not changed in the presence of a range of THU concentrations from 10' to 10-7 M. Inhibition by THU was slightly enhanced by preincubation of enzyme and inhibitor, as shown in Table V . This enhancement of inhibition was, most noticeable at high concentrations of substrate relative to inhibitor.
A number of other compounds, including uridine, deoxyuridine, UMP, CTP, and UTP, weakly inhibited the deamination of cytidine, but only when the inhibitor concentration was severalfold greater than substrate. The apparent K6 for UTP inhibition was 1.2 X 10-' M. Further comnparison of normal and leukemic enzymes. The enzymes from normal and leukemic cells were further compared with respect to substrate specificity and kinetic properties. The enzyme from CML cells was active against the same spectrum of compounds, including the halogenated derivatives and deoxynucleosides that served as substrates for the enzyme from normal granulocytes. A comparison of the kinetic properties of the most highly purified fractions (see Table II ) of normal and CML and AML deaminase revealed no apparent differences in the deaminase enzymes from these three cell types. The apparent Km's for the substrate cytidine were 1.1, 1.1, and 1.8 X 10' M respectively for the normal, CML, and AML enzymes, while the Ks's for Relationship of cell naturity to enizyme levels. The decreased deaminase levels in leukemic cells could be due to a disease-related deficiency or structural alteration of the deaminase of leukemic cells, or alternatively might simply be due to the immaturity of leukemic cells. To determine whether normal granulocyte maturation is associated with an increase in intracellular deaminase levels, normal human bone marrow aspirates were separated into mature and immature myeloid fractions by centrifugation in a Ficoll density gradient. These studies revealed a 3.55-to 14.2-fold greater specific activity of cytidine deaminase in the mature cell fraction (predominantly polymorphonuclear leukocvtes, bands, and metamyelocytes) as compared to the immature fraction (predominantly myelocytes, promyelocytes, and myeloblasts) ( (Table I ).
These data suggest that deaminase activity appears during or before the myelocyte stage of maturity, but achieves maximal levels only in the later stages of maturation, both in normal and leukemic granulocytes.
Subcellular localization of cytidine deaminase. Because the appearance of deaminase activity parallels the development of cytoplasmic granules, the subcellular localization of this enzyme in mature granulocytes was examined. 85% of the activity present in the crude cell homogenate was recovered in the soluble portion of the cell, and only 0.8% in the granule fraction that contained the lysozomal enzyme, myeloperoxidase.
DISCUSSION
The present report has described the purification and properties of cytidine deaminase from normal and leukemic granulocytes. This granulocyte enzyme was first noted by Silber, Gabrio, and Huennekens in 1963 (9) and was differentiated from deoxycytidylate deaminase in a subsequent report (10) . The separate identities of cytidine deaminase and deoxycytidylate deaminase were confirmed in the present study by selective heat inactivation of the nucleotide deaminase and the failure of dCMP to competitively inhibit deamination of cytidine.
Comparison of the deaminase enzymes from normal, CML, and ANIL granulocytes failed to disclose biochemical or kinetic differences, but showed significantly lower levels of enzyme in leukemic cells as opposed to normal granulocytes, as was suggested by earlier studies (10) . This difference in enzyme activity appears related to the immaturity of the leukemic cells, in that the present experiments have shown an increase in the intracel-lular deaminase levels associated with maturation of both normal and CML granulocytes.
Previous studies have shown differences in specific enzyme levels in leukemic as opposed to normal granulocytes. Increased levels of DNA polymerase (23), dihydrofolate reductase (24) , aspartate transcarbamylase (25) , dihydro-orotase (25) , and dihydro-orotic dehydrogenase (25) have been observed in AML cells as compared to normal granulocytes. Rabinowitz (23) related the increased activity of DNA polymerase to immaturity of the leukemic cells by showing a decrease in polymerase activity during maturation of normal granulocytes; a similar correlation was not attempted in the other enzyme studies. Gallo (26) has partially purified and characterized thymidine phosphorylase from human granulocytes and has found a lower level of this enzvme in CML cells as compared to normal granulocytes. The possibility was raised that this finding represented a specific enzyme deficiency related to the leukemic state. It is apparent from the present work, however, that marked increases may occur in enzyme levels during maturation of the normal or CMIL granulocyte, and that these changes must be taken into consideration in investigatioIns of the biochemistry of malignant cells.
The granulocyte deaminase characteristized in this study shares several characteristics withl the deaminase previously described in human liver homogenates by Camiener, including its heat stability, substrate specificity, and a Michaelis constant for ara-C of ca. 10-' M (5, 27-29). However, certain differences in substrate affinity and THU inhibition are apparent. The liver homogenate activity described by Camiener had approximately equal affinity for ara-C and 5-azaC, as defined by the competitive inhibition of ara-C deamination by 5-azaC. This contrasts with the fivefold difference in Michaelis constants for ara-C and 5-azaC observed with the granulocyte enzyme in the present study.
In addition, the inhibition of human liver deaminase by THU was described as partially noncompetitive (22); a threefold decrease in maximum velocity for ara-C was observed in the presence of 3.3 X 10' M THU. In the present study, THU in the same concentration did not alter the maximum velocity of the normal human granulocyte enzyme with either cytidine or deoxycytidine as substrates and appeared to inhibit the granulocyte deaminase competitively. Preincubation of the liver deaminase with THU in the absence of substrate markedly enhanced inhibition, while in the present experiments, preincubation of granulocyte deaminase and THU for 5 min only slightly enhanced inhibition. The affinity constant, or Ki, of THU for the partially purified granulocyte deaminase in the present study was 5.4 X 10 M, while that reported for the crude liver deaminase was between 10-' and 10-M. It is possible, although unlikely, that differences in the enzyme purity, pH (7.5 vs. 8.0) and buffer (Tris-Cl vs. glycylglycine in KrebsRinger) used in these two studies could account for the marked differences in THU inhibition of the granulocyte and liver cytidine deaminase. It is also possible that these differences are due to the presence of multiple enzymes in the liver homogenate or to a basic difference in deaminases in these two tissues. Further studies of purified liver deaminase would be required to resolve this problem.
It is unusual that a reduced uridine derivative such as THU would function as a powerful competitive inhibitor of cytidine deaminase. However, this inhibition may result from the structural similarity that THU bears to cytidine-3,4-monohydrate, a possible transition state compound in the deaminase reaction (30) . The reaction mechanism of cytidine deaminase has not been defined in detail, but analogous hydrated intermediates and inhibitors have been identified in the adenosine deaminase reaction (31, 32) .
Other cytidine deaminases from leukemic mouse spleen (33), sheep liver (34) , and mouse kidney (35, 36) have been partially purified and characterized. The enzyme from human granulocytes has a distinctly lower Michaelis constant for cytidine and a broader pH maximum than the other enzymes. Sufficient data from earlier studies were not available to allow comparison of other properties such as molecular weight, isoelectric point, and inhibition by THU.
Cytidine deaminase is responsible for the inactivation of two important pharmacologic agents, ara-C (5) and 5-azaC (8), both of which are widely used in the treatment of AML. The mechanism of clinical resistance to these agents has not been defined; most resistant animal tumors appear to lack the kinase necessary for ara-C activation (37, 38) , but a recent study suggested a decreased response rate to ara-C in cases of AML having elevated deaminase activity before therapy, or showing a rise in deaminase levels during therapy with ara-C (11). In addition, Meyers et al have demonstrated the induction of cytidine deaminase in vitro in HeLa cells exposed to low levels of ara-C (39). High deaminase levels, which would be a disadvantage in treatment with ara-C or 5-azaC, might provide a selective advantage for agents such as the 5-halogenated derivatives of cytidine. Thus, 5-fluorocytidine, which has a greater maximum velocity than the physiologic substrates and ara-C, would be readily converted to the active antineoplastic agent, 5-fluorouridine (40) , by cells with increased deaminase activity, and might be a therapeutic agent in patients resistant to ara-C or 5-azaC on the basis of increased deaminase.
